Latest News

• FLAG Therapeutics Secures Over $500,000 in Equity and Impact Funding from Venture and Mission-Driven Investors, Including Springhood Ventures, Kids Beating Cancer, The Musella Foundation, the AYJ Fund, Tough2gether Foundation and DDRFA        

  Big news! The Musella Foundation teamed up with Kids Beating Cancer, the AYJ Fund, Tough2gether Foundation, DDRFA, and Springhood Ventures to help FLAG Therapeutics raise over $500,000 to push their promising drug, FLAG-003, toward clinical trials for kids with DIPG.

  FLAG-003 has shown great results in preclinical testing. It crosses the blood-brain barrier and kills tumor cells through two powerful mechanisms, while sparing healthy cells. This could be a game-changer for DIPG and other brain tumors.

  We're proud to be part of this initial funding, but we need to help them raise a lot more money to get this treatment to the kids who need it! If your organization wants to join in, contact me at musella@virtualtrials.org. Individuals can donate at virtualtrials.org/donate and mention it's for the FLAG project!

  
  
• Servier Announces Positive Findings from Longer-Term Analysis of Phase 3 INDIGO Trial Showing Continued Durable Effect of Voranigo        

  A longer-term analysis of the Phase 3 INDIGO trial was just published in The Lancet Oncology, and it confirms the durable benefit of Voranigo (vorasidenib)—the first targeted therapy FDA approved for Grade 2 IDH-mutant glioma in 2024. With an additional six months of trial follow-up, patients on Voranigo continued to show prolonged progression-free survival and delayed need for further intervention compared to placebo, along with sustained reductions in tumor growth and seizure frequency and no new safety issues. These data strengthen confidence that Voranigo offers meaningful and durable disease control for patients with low-grade IDH-mutant glioma. Use of the drug in Grade 3 or 4 IDH-mutant brain tumors remains investigational, but there are some ongoing studies that will hopefully yield evidence on the impact in higher grade tumors in the near future.